Skip to main content
Beth Israel Deaconess Medical Center
Primary menu
  • Home
  • Our Team
  • Research
  • Fellowship & Education
  • Publications
  • News and Archives

In transfusion-dependent, angiodysplasia-related anemia, adding octreotide to usual care reduced transfusions at 1 y.

Flynn, Duncan J, and Joseph D Feuerstein. 2024. “In Transfusion-Dependent, Angiodysplasia-Related Anemia, Adding Octreotide to Usual Care Reduced Transfusions at 1 Y.”. Annals of Internal Medicine 177 (6): JC69.
Publisher's Version

Abstract

Goltstein LC, Grooteman KV, Bernts LH, et al. Standard of care versus octreotide in angiodysplasia-related bleeding (the OCEAN study): a multicenter randomized controlled trial. Gastroenterology. 2024;166:690-703. 38158089.

Last updated on 07/28/2025
PubMed

Selected Publications

  • Mistakes in therapeutic drug monitoring of biologics in IBD and how to avoid them
  • Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
  • Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
  • A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
  • Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
  • Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
More
Contact Us

330 Brookline Avenue

Boston, MA, 02215

Powered byOpenScholar®Admin Login